Kexing Biopharm’s Overseas Products Bevacizumab and Sorafenib Approved for Marketing in Syria

Article source：May 21,2026View： 373

Recently, both the bevacizumab biosimilar and sorafenib tosylate tablets for overseas markets by Kexing Biopharm have been formally approved for marketing by the Syrian Ministry of Health (MoH).

Two Major Oncology Drugs Addressing Unmet Clinical Needs

The two products approved in Syria are both core oncology therapeutics with broad clinical applications and well-established market demand.

Bevacizumab, a biosimilar co-developed and commercialized overseas by Kexing Biopharm in collaboration with Mabwell (Dongyao Biopharm), is one of the earlier approved domestic bevacizumab biosimilars. It is widely used in the treatment of multiple cancers, including metastatic colorectal cancer, advanced/metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and cervical cancer,etc.

Sorafenib tosylate tablets are targeted anti-cancer drugs developed for overseas markets by Kexing Biopharm in collaboration with Yabao Pharmaceutical. Clinically, they are primarily used for the treatment of unresectable or metastatic hepatocellular carcinoma and advanced renal cell carcinoma.

Drug registration in Syria is centrally regulated and approved by the Ministry of Health (MoH). The review process references technical standards from authoritative international organizations such as the WHO and the FDA, with stringent requirements for pharmaceutical quality systems, safety, and efficacy data. Syria has a strong reliance on imported oncology medicines, and there is significant clinical demand for high-quality, cost-effective therapies. The approval of these two products is expected to provide local patients with more affordable and stable access to high-quality cancer treatments.

Expanding Presence in the MENA Pharmaceutical Market, Accelerating Overseas Commercialization

Kexing Biopharm has established a relatively comprehensive presence across the MENA region. Multiple overseas products have already been approved in countries such as Egypt, Saudi Arabia, Oman, and the United Arab Emirates, while market expansion in other countries is steadily progressing. The successive approvals of these two products in Syria further enrich the company’s product portfolio in the region.

In terms of partnerships, the company has established overseas collaboration agreements with multiple well-known domestic pharmaceutical companies, forming a tightly integrated cooperation mechanism covering the entire value chain. This enables efficient complementarity with partners in manufacturing quality management, overseas regulatory registration, and marketing and commercialization.

Looking ahead, the company will continue contributing to improving the accessibility of high-quality medicines and bringing benefits to patients worldwide.